Sanofi’s Lemtrada beats Rebif in head-to-head MS showdown

Sanofi has rolled out a fresh set of late-stage Lemtrada (alemtuzumab) data demonstrating its superiority to Rebif in a head-to-head matchup for multiple sclerosis. One of the key programs acquired in…
Read the full story: News